Skip to content

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
CTO
Citius Oncology, Inc.CTOR
$35.27M-1.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$21.04M-122%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$240.68M+388%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$870.01M-47.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$68.32M-44.3%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s total equity?
TuHURA Biosciences, Inc. (HURA) reported total equity of $23.19M in Q1 2026.
How has TuHURA Biosciences, Inc.'s total equity changed year-over-year?
TuHURA Biosciences, Inc.'s total equity increased by 135.3% year-over-year, from $9.86M to $23.19M.
What is the long-term trend for TuHURA Biosciences, Inc.'s total equity?
Over 4 years (2021 to 2025), TuHURA Biosciences, Inc.'s total equity has grown at a 10.4% compound annual growth rate (CAGR), from $14.1M to $20.93M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.